Lambert-Eaton Myasthenic Syndrome (LEMS) is most closely associated with which cancer and presents with proximal weakness due to impaired acetylcholine release?

Prepare for the American Board of Professional Psychology (ABPP) Exam with flashcards and multiple-choice questions. Each question includes insights and explanations to help you excel. Get ready for your certification journey!

Lambert-Eaton Myasthenic Syndrome reflects a paraneoplastic neuromuscular problem where autoantibodies target presynaptic voltage-gated calcium channels, reducing calcium influx and thus acetylcholine release at the neuromuscular junction. This loss of ACh release produces proximal muscle weakness, which characteristically can improve with repeated use or rapid, high-frequency activity because facilitation increases calcium entry and transiently boosts transmitter release. LEMS is most strongly associated with small cell lung carcinoma, which is why recognizing this syndrome in the setting of cancer points you toward the same paraneoplastic mechanism. The key contrast is with myasthenia gravis, where weakness stems from antibodies against postsynaptic acetylcholine receptors, not presynaptic calcium channels. Among the provided options, the term that best captures this cancer-linked presynaptic neuromuscular disorder is Lambert-Eaton Myasthenic Syndrome. The other choices describe tumors or conditions not characterized by the presynaptic defect leading to impaired ACh release.